ConcertAI
ConcertAI is an AI-powered SaaS and real-world data company specializing in oncology, serving top pharmaceutical companies and major healthcare systems with clinical trial optimization, real-world evidence, and commercial analytics built on its proprietary CARAai multi-LLM platform.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingSoftware
What ConcertAI does
ConcertAI is an AI-powered SaaS and real-world data company specializing in oncology and other complex diseases, founded in 2017 and headquartered in Cambridge, Massachusetts, operating as a subsidiary of SymphonyAI. The company develops the CARAai platform — a proprietary multi-LLM and agentic AI intelligence layer that extracts oncology variables from unstructured clinical text, powers multi-agent workflows, and grounds outputs against published literature — which underpins its entire product portfolio. Its core offerings span three product lines: (1) the Precision Suite for real-world evidence, including Patient360, Precision360, Translational360, and Precision Explorer, aggregating 13M+ patient records from approximately 1,000 cancer centers integrated with genomic partners Foundation Medicine, Guardant, NeoGenomics, and Caris; (2) Clinical Development solutions including Accelerated Clinical Trials (ACT), an agentic AI platform launched in February 2026 that automates the trial lifecycle, plus TriaLinQ for trial matching; and (3) Commercial Solutions including Cadence Suite, an AI-native application suite for pharmaceutical field teams launched in April 2026. The company also owns the CancerLinQ oncology intelligence network (acquired from ASCO in December 2023), covering 900+ care sites across all 50 states, and TeraRecon, an enterprise imaging platform for MRI/CT visualization and AI biomarker detection acquired via merger in November 2021.
ConcertAI serves two primary customer segments: (a) top-tier life sciences and pharmaceutical companies — it claims 75% of the top 30 life sciences clients and 45+ biopharma partners including AbbVie, AstraZeneca, Eli Lilly, Amgen, Merck, Regeneron, Bayer, and Jazz Pharmaceuticals — and (b) oncology healthcare providers and systems — approximately 50% of the top 250 global healthcare systems, including Mayo Clinic, Duke Health, Penn Medicine, and NHS England. The company monetizes primarily through multi-year enterprise SaaS subscriptions (Clinical Trials, RWE, Commercial, CancerLinQ, TeraRecon), Data-as-a-Service access to its multi-modal oncology datasets, and Professional Services for custom dataset curation, analytics, and regulatory-grade evidence generation. Pricing is custom and quote-based; no public pricing exists. The company maintains a sales-led, enterprise-field-sales go-to-market model with offices in the US, India (Bangalore), Germany (Frankfurt), and Japan (Tokyo).
Recent operating indicators include 1,001–5,000 employees, 500+ peer-reviewed scientific publications using ConcertAI data, 1,900+ global healthcare provider settings where its technologies are deployed, and recognition as a 2026 Fast Company Most Innovative Company and 2026 Frost Radar leader in AI-enabled clinical trials. The company is privately held; its most recent funding round was a $150 million Series C led by Sixth Street in March 2022 at a $1.9 billion post-money valuation.
ConcertAI firmographics
Firmographics- Name
- ConcertAI
- Legal name
- ConcertAI LLC
- Website
- https://concertai.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- ConcertAI is an AI-powered SaaS and real-world data company specializing in oncology, serving top pharmaceutical companies and major healthcare systems with clinical trial optimization, real-world evidence, and commercial analytics built on its proprietary CARAai multi-LLM platform.
- Ownership category
- akta.pro rank
ConcertAI industry classification
Industry- Product category
- Oncology AI & Real-World Evidence SaaS
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where ConcertAI is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
ConcertAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Enterprise AI SaaS Subscriptions: Subscription-based SaaS solutions for life sciences companies and healthcare providers. Includes clinical trials, real-world evidence, and commercial solutions platforms.
- Data-as-a-Service (DaaS): Access to proprietary multi-modal oncology datasets including Patient360, Translational360, and Precision360 for evidence generation and research.
- Clinical Trial Solutions: Enterprise solutions for clinical trial design, site selection, and patient recruitment optimization delivered as SaaS subscriptions.
- Professional Services: Scientific services including custom dataset curation, analytical services, and consulting for regulatory-grade evidence generation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise contracts with custom pricing based on solution scope and data access requirements |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
ConcertAI product offering
Product offeringCore offering
ConcertAI is an AI-powered SaaS and real-world data technology company that builds oncology-focused enterprise platforms combining proprietary multi-modal datasets (13M+ patient records), agentic AI analytics, and clinical workflow tools. Its products enable life sciences companies to optimize clinical trials, generate regulatory-grade real-world evidence, and run commercial pharmaceutical operations, while giving healthcare providers an oncology intelligence network for quality measurement and clinical decision support.
Product overview
ConcertAI is a predictive and generative AI SaaS and real-world data technology company serving life sciences, healthcare, and oncology. The company's offerings follow a platform-plus-modules architecture centered on the CARAai AI intelligence layer. The CARAai platform provides clinical concept extraction, contextual understanding, and multi-source processing capabilities across the portfolio. Key product lines include: Precision Suite (Precision360, Precision Explorer, Translational360, Patient360, Scientific Services) for real-world evidence and regulatory research; Clinical Development solutions including ACT (Accelerated Clinical Trials) and TriaLinQ for clinical trial optimization; Commercial Solutions featuring Cadence Suite and Data Foundry for pharmaceutical commercial teams; CancerLinQ Suite providing oncology provider tools including SmartLinQ with clinical quality, trial matching, and cohort matching; and TeraRecon enterprise imaging solutions including Advanced Visualization (AV, Intuition), DETECT for AI-powered biomarker detection, and AI Framework. The platform integrates multimodal data including EHR, claims, genomic, imaging, and social determinants of health to support evidence generation, clinical trials, and commercial applications across oncology and complex diseases.
Differentiator
Problem solved
Functional benefit
Brands
- CancerLinQ: An initiative of ConcertAI providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified quality solutions and SmartLinQ analytic services. CancerLinQ represents one of the largest oncology real-world data and quality of care technology service entities.
- TeraRecon
- CARAai
- Cadence Suite
- ACT (Accelerated Clinical Trials)
Products and services
- CARAai (Clinical and Research Accelerator) AI platform that serves as the intelligence layer across ConcertAI's product portfolio, extracting key oncology variables (treatment response, metastatic status, stage, ECOG), interpreting implicit and ambiguous clinical references, and processing notes, radiology reports, and labs. Powers multi-LLM and agentic AI capabilities for life sciences and healthcare customers.
- Precision360 Real-world evidence dataset offering weekly AI-curated oncology data from the CancerLinQ network, with comprehensive in-depth coverage for solid and hematologic cancers and access to 13M+ de-identified patient records for life sciences customers.
- Translational360 Clinico-genomic dataset combining clinical and biological data for translational research, integrating DNA mutations, RNA expression, and clinical outcomes within a single framework with 100+ curated clinical variables and 500K combined clinical and biological datasets.
- Patient360 Foundational deeply curated real-world dataset for on-demand evidence generation that integrates EHR, claims, genomic, and social determinants of health data, providing a 360-degree view of the patient journey with 200+ biomarkers and 100+ curated variables from a 13M patient datalake.
- Accelerated Clinical Trials (ACT) Enterprise agentic AI platform built on the CARAai framework that automates and optimizes the full clinical trial lifecycle, leveraging real-world data and predictive analytics to support protocol design, site selection, patient recruitment, and study management for trial sponsors and CROs.
- Cadence Suite AI-native application suite for pharmaceutical commercial and field teams that identifies and resolves patient access barriers (prior authorization delays, coverage confusion, pharmacy stockouts), unifying specialty pharmacy data, claims data, and social determinants of health into a connected view powered by CARA agentic AI.
- CancerLinQ Suite Oncology intelligence platform providing real-world evidence drawn directly from everyday care, with a network of 100+ cancer centers and oncology practices, 10 EMR integrations, and data from nearly 7 million patient records. Includes SmartLinQ SaaS with clinical quality, ASCO-aligned QOPI and ASCO Certified, trial matching, and cohort matching capabilities for oncology providers.
- TeraRecon AV (Advanced Visualization) Advanced medical imaging visualization providing high-performance clinical visualization for MRI and CT, including TeraRecon Intuition for high-performance viewing capabilities, used by radiology departments and enterprise imaging customers.
- TeraRecon DETECT AI-powered biomarker detection tool for clinical and operational workflows in medical imaging, enabling integration of imaging AI into coordinated clinical workflows for radiology and oncology use cases.
- Scientific Services Consultative evidence generation services providing custom datasets, rapid analytics, regulatory-grade evidence generation, and translational insights delivered by a team of epidemiologists, biostatisticians, and data scientists.
- Precision Explorer Real-world data insights platform that generates AI insights from RWD using hallucination-free citations from published literature and comparisons to standards of care, built with the CARA AI engine.
- Data Foundry Data platform providing real-time insights and actionable intelligence for understanding patient journeys in commercial pharmaceutical applications.
- Precision GTM Go-to-market intelligence solution driving engagement and patient access for pharmaceutical commercial teams.
Quantifiable outcome
- Reduces clinical trial timelines by 10-20 months
- +5 more outcomes
Companies that use ConcertAI
Customer profileNamed customers14 records
Segments3 records
Ideal customer profiles2 records
ConcertAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability12 records
Feature7 records
ConcertAI partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and major.
- Foundation MedicinecoreCollaboration combining Foundation Medicine's genomic testing data with ConcertAI's clinical data to create the largest clinically-linked dataset in the industry, encompassing nearly 500,000 patients for translational research and drug development.
- NeoGenomicscoreCollaboration advancing large-scale hematological research solutions combining ConcertAI's longitudinal clinical data with NeoGenomics' comprehensive biomarkers. Dataset covers over one million patient lives across 1,000+ oncology clinics.
- NVIDIAcoreStrategic collaboration integrating NVIDIA NIM microservices, CUDA-X microservices, and NeMo platform into ConcertAI's suite of AI solutions. Powers scalable, enterprise-ready AI orchestration for clinical development.
- Amazon Web Services (AWS)coreTechnology partner powering scalable, secure intelligence infrastructure built for healthcare and life sciences demands.
- Guardant HealthcoreData-sharing partnership to develop multi-modal real-world data solutions for cancer care, combining liquid biopsy and clinical data for comprehensive oncology insights.
- Caris Life SciencescoreLab partner integrating deep genomic and molecular insights into real-world clinical intelligence through data collaboration.
- BayermajorMulti-year agreement for AI-powered clinical trial solutions, integrating ConcertAI's ACT platform into Bayer's clinical development programs.
- NeoGenomics (clinical trials)majorMulti-year agreement for AI-enabled clinical trial optimization and site selection solutions in oncology.
- ASCO (American Society of Clinical Oncology)coreAcquired CancerLinQ from ASCO in 2023, continuing expansion with ASCO Certified quality framework and ASCO-aligned solutions. ASCO remains a key medical society partner.
- Guardant Health (commercial goals)majorMutual commercial objectives established for the data-sharing deal aimed at advancing cancer therapy commercialization.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
ConcertAI competitors and assessment
Company assessmentDirect peers
- Flatiron Health: Roche-owned oncology real-world data and EHR company serving academic centers, community oncology, and life sciences. Direct competitor to ConcertAI's oncology RWE and clinical trial enablement franchises with deep biopharma penetration.
- Tempus AI: AI-powered precision medicine company combining genomic sequencing, real-world data, and AI applications for oncology and other disease areas. Closest direct competitor to ConcertAI on multi-modal oncology data, clinical trial matching, and biopharma RWD.
- Medidata Solutions (Dassault Systèmes): Industry-leading clinical trial technology platform (Rave EDC, CTMS, eCOA) used by most large biopharma sponsors. Direct competitor in clinical trial informatics, with strong overlap to ConcertAI's ACT and TriaLinQ offerings.
- COTA Healthcare: Oncology-focused real-world data and analytics company serving providers, payers, and life sciences. Direct competitor in curated oncology RWE with similar customer segments as ConcertAI's CancerLinQ and Precision360 franchises.
- Syapse: Real-world evidence company focused on oncology, partnering with health systems and life sciences to deliver insights for precision medicine. Direct competitor in oncology RWE and provider data partnerships analogous to CancerLinQ.
Broad incumbents
- IQVIA: Largest life sciences technology and clinical research services provider, with RWE, clinical trial, and commercial analytics franchises. Overlaps with ConcertAI across clinical trial optimization, RWE, and pharma commercial, but operates across all therapeutic areas, not oncology-only.
- Veeva Systems: Cloud software provider for life sciences, including clinical, regulatory, and commercial applications. Overlaps with ConcertAI in clinical trial operations, real-world evidence, and pharma commercial workflows at large biopharma accounts.
- Palantir Technologies: Enterprise data and AI platform with growing footprint in healthcare and life sciences, including clinical trial acceleration and RWE. Overlaps with ConcertAI's data-platform and AI layer (CARAai) and is increasingly competing for biopharma data-infrastructure spend.
Emerging players
- Foundation Medicine: Roche subsidiary providing comprehensive genomic profiling in oncology; both a partner (Foundation Medicine clinico-genomic collaboration, ~500K patients) and adjacent competitor as a source of oncology data feeding into life sciences R&D workflows.
- TriNetX: Global health research network linking providers, biopharma, and CROs for clinical trial design, site selection, and real-world evidence. Comparable to ConcertAI's CancerLinQ/TriaLinQ trial-matching and RWE capabilities, with a broader therapeutic footprint.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
ConcertAI social profiles
Digital presenceConcertAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
ConcertAI leadership team
Management profileNumber of profiles
Profiles18 records
ConcertAI subsidiaries and ownership
Company hierarchySubsidiaries2 records
ConcertAI funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ConcertAI M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ConcertAI
What does ConcertAI do?
ConcertAI is an AI-powered SaaS and real-world data technology company that builds oncology-focused enterprise platforms combining proprietary multi-modal datasets (13M+ patient records), agentic AI analytics, and clinical workflow tools. Its products enable life sciences companies to optimize clinical trials, generate regulatory-grade real-world evidence, and run commercial pharmaceutical operations, while giving healthcare providers an oncology intelligence network for quality measurement and clinical decision support.
Is ConcertAI a public or private company?
ConcertAI is a private company. It is classified as corporate owned and is currently operating.
When was ConcertAI founded?
ConcertAI was founded in 2017. It employs 1,001 to 5,000 people.
Where is ConcertAI based?
ConcertAI is headquartered in Cambridge, United States, in the North America region.
How does ConcertAI make money?
Four revenue lines are on record. Enterprise AI SaaS Subscriptions are the primary driver. The others are data-as-a-Service (DaaS), clinical Trial Solutions and professional Services.
Who are ConcertAI's main competitors?
Direct peers on record are Flatiron Health, Tempus AI, Medidata Solutions (Dassault Systèmes), COTA Healthcare and Syapse. Broad incumbents are IQVIA, Veeva Systems and Palantir Technologies. Emerging players are Foundation Medicine and TriNetX.
Does ConcertAI have an API?
No public API is recorded for ConcertAI.
What industry is ConcertAI in?
ConcertAI's product category is Oncology AI & Real-World Evidence SaaS. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 54171 and its SIC code is 8731.